How it works: Reaching inflammation inside the brain →

Cenrifki

EU: Approved in the EU since 2026US: Not FDA approved

Molecule type
Small molecule
Mechanism (ChEMBL)
Tyrosine-protein kinase BTK inhibitor
Targets
Tyrosine-protein kinase BTK
Availability
Authorised in all EU and EEA countries. Reimbursement is decided by each country.

Approvals

  • EU/EEACenrifki · Authorised2026-06-19 Source

Safety communications

None recorded.

Trials

Key trials

Large trials with a reported result on their main goal.

  • HERCULES

    Completed · Phase 3 · Progressive MS · Main goal met

  • GEMINI 1

    Completed · Phase 3 · Relapsing MS · Main goal not met

  • GEMINI 2

    Completed · Phase 3 · Relapsing MS · Main goal not met

Running now

  • ORION

    Recruiting · MS (type not specified) · ongoing

  • MSBenefiT

    Not yet recruiting · Phase 3 · MS (type not specified) · ongoing

  • Tolebrutinib, phase 3

    Running, not recruiting · Phase 3 · Relapsing and progressive · ongoing

  • Tolebrutinib, phase 3

    Running, not recruiting · Phase 3 · Relapsing and progressive · ongoing

Other trials (7)

Completed small trials, dose-finding studies and trials in other diseases.

For information only, not medical advice. Talk to your neurologist before changing treatment.

Hypotheses involving this medicine

Loading hypotheses…

Loading reviews and guidelines…

Lab studies

Lab studies in animals or cells. Results in animals often do not hold in people, and these studies never change the status of an idea.

Loading lab studies…

Assembled by software from public sources and not checked by people. Each record links to its source. Report an error